Navigation Links
Sigma-Aldrich Offers Customizable Synthetic Extracellular Matrix for Stem Cell Research
Date:8/13/2009

ST. LOUIS, Mo., Aug. 13 /PRNewswire-FirstCall/ -- Sigma-Aldrich(R) (Nasdaq: SIAL) today announced an agreement with Glycosan BioSystems for the sale of HyStem(TM), a fully customizable synthetic extracellular matrix (ECM) for stem cell research. HyStem offers researchers flexibility to tailor microenvironments for their cultured cells that mimic natural in vivo conditions, optimizing stem cell proliferation and differentiation. HyStem was developed by Glycosan BioSystems and will be sold by Sigma-Aldrich under a non-exclusive distribution agreement (http://www.sigma.com/hystem).

The HyStem platform consists of hydrogel cell culture scaffolds that provide a complex, three dimensional environment in which cells are able to proliferate, much as they would in vivo. Composed of hyaluronic acid and denatured collagen, HyStem's synthetic matrix offers greater control of the cellular environment than ambiguous extracted ECM alternatives. Customizable microenvironments enable researchers to optimize the growth conditions for each distinct cell type in a multicellular organism.

"Our HyStem ECMs provide a new level of control over the stem cell growth environment than what was previously available to the research community. We believe this ECM platform will greatly aid researchers in advancing global stem cell research," said Dr. David Smoller, President of Sigma-Aldrich's Research Biotech business unit. "Sigma-Aldrich provides more than 1,100 unique, highly-focused products to support every aspect of the stem cell research workflow, from isolation, characterization, expansion, differentiation and functional profiling to in vitro/in vivo tracking. The addition of HyStem products to our portfolio enhances our position as a leading source of technologies that support the growing stem cell market."

The HyStem platform includes three unique options: HyStem, HyStem-C and HyStem-HP. HyStem is available to researchers who want to customize their own attachment factors, ECM proteins and peptides, and who require an animal-component-free system with a minimal number of cell attachment sites. Researchers requiring a large number of generalized cell attachment sites for their stem cell cultures will benefit from HyStem-C. HyStem-HP is available for scientists planning to incorporate and gradually release growth factors into the stem cell environment. All options are consistently formulated and well characterized for both in vivo and in vitro experimentation.

Sigma-Aldrich's regenerative medicine experts continue to identify and develop promising technologies that support this rapidly-evolving research area. HyStem expands the Sigma-Aldrich portfolio of advanced stem cell research technologies, available through the company's web portal at http://www.sigma-aldrich.com/stemcell.

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company. Its biochemical and organic chemical products and kits are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development and as key components in pharmaceutical, diagnostic and other high technology manufacturing. The Company has customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 38 countries and has 7,800 employees providing excellent service worldwide. Sigma-Aldrich is committed to Accelerating Customer Success through Innovation and Leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit its award-winning Web site at http://www.sigma-aldrich.com.

Cautionary Statement: This release contains forward-looking statements relating to future performance, goals, strategic actions and initiatives and similar intentions and beliefs and other statements regarding the Companies' expectations, goals, beliefs, intentions and the like, which involve assumptions regarding the Companies' operations and conditions in the markets the Companies serve. The Companies do not undertake any obligation to update these forward-looking statements.

Sigma-Aldrich is a registered trademark of Sigma-Aldrich Biotechnology LP and Sigma-Aldrich Co. HyStem, HyStem-C and HyStem-HP are trademarks of Glycosan BioSystems, Inc.


'/>"/>
SOURCE Sigma-Aldrich
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Sigma-Aldrich (Nasdaq: SIAL) Reports 6% Increase In First Quarter 2009 Diluted EPS to $0.68. All Research Units Achieve Organic Sales Growth. Full Year 2009 Guidance Reaffirmed; Diluted EPS Expected to Exceed Reported EPS for 2008 of $2.65.
2. Sigma-Aldrich Announces Appointment of Michael Kanan as Vice President and Corporate Controller
3. Sigma-Aldrich Enters Distribution Agreement With AlphaGenix, Inc.
4. Sigma-Aldrich and Atlas Antibodies Announce the Release of 2,000 New, Highly-Validated Prestige Antibodies
5. Sigma-Aldrich Shareholders Elect Directors and Ratify Auditor; Directors Declare Quarterly Dividend
6. Sigma-Aldrich Amends Credit Facility and Expands Commercial Paper Program
7. Sigma-Aldrich Licenses From NeuroSurvival Technologies a Leading Marker for Molecular Imaging of Apoptosis in Vivo
8. Sigma-Aldrich Announces mirPremier(TM) microRNA Isolation Kit for miRNA Purification
9. Living Peacefully in a Big City: Natural Health Practitioner Offers Advice on Maintaining Sanity, Health and Happiness
10. Institute Chastises Congress on Health Care Reforms, Offers Five-Point Program for Reducing Health Care Costs by 50%
11. Gene Therapy Offers Hope Against Inherited Blindness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, ... Elite. The attorneys chosen by their peers for this recognition are considered among the ... Traurig Shareholders received special honors as members of this year’s Legal Elite Hall of ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway ... call for a minimum wage raise to $12 an hour by 2020 and then adjusting ... restore the lost value of the minimum wage, assure the wage floor does not erode ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Living, is proud to recognize Dr. Barry M. Weintraub as a prominent plastic ... most beautiful women in the world, and the most handsome men, look naturally ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm Slone ... executive with extensive sequencing and genomics experience, as Vice President of North American Capital ... will be responsible for leading the sales team in the commercialization of the HTG ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the ... report to their offering. ... favourable commercial environment for MedImmune to enter. The US ageing ... serve to drive considerable growth for effective anti-influenza medications. The ... sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)... RIDGE, Ill. and INDIANAPOLIS ... of students receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship ... The 2016 scholarship winners, announced today online at ... to let type 1 diabetes stand in the way ... Diabetes has supported the Foundation,s scholarship program since 2012, ...
(Date:6/23/2016)... N.J. , June 23, 2016  Guerbet announced ... Premier Inc.,s Supplier Horizon Award . ... year, Guerbet was recognized for its support of Premier ... creation through clinical excellence, and commitment to lower costs. ... to receive this recognition of our outstanding customer service ...
Breaking Medicine Technology: